Kwamie Y, Persad E, Stancer H
Can J Psychiatry. 1984 Nov;29(7):605-8. doi: 10.1177/070674378402900712.
This is a report of an open clinical trial of Carbamazepine in the treatment of patients who suffered from affective disorders and who did not have an adequate response to Lithium or other medications. Our findings suggest that Carbamazepine can be a useful adjunctive medication when used in combination with Lithium and other psychotropic medications. The characteristics of the patients who responded were examined. The clinical state of the patients at the point of intervention varied; eight patients were manic and four patients were depressed. Four patients were judged to have had markedly effective responses, four showed an effective response and in four there was a slightly effective response. From the duration of the trials it was evident that in cases where Carbamazepine produced a good response its effect was seen as early as two weeks. The mean daily dose used varied from 300-1300 mgs. Because of the open nature of this trial, Carbamazepine was not withdrawn except in one instance.
这是一份关于卡马西平治疗情感障碍患者的开放临床试验报告，这些患者对锂盐或其他药物反应不佳。我们的研究结果表明，卡马西平与锂盐及其他精神药物联合使用时，可作为一种有用的辅助药物。对有反应的患者特征进行了检查。干预时患者的临床状态各不相同；8名患者为躁狂发作，4名患者为抑郁发作。4名患者被判定有显著有效反应，4名患者显示有效反应，4名患者有轻微有效反应。从试验持续时间来看，很明显在卡马西平产生良好反应的病例中，其效果早在两周时就可见到。平均每日剂量为300 - 1300毫克。由于本试验的开放性，除了1例之外，卡马西平均未停药。
